Alopecia areata (AA) is an autoimmune inflammatory disorder characterised by non-scarring hair loss. Baricitinib is the first oral Janus kinase inhibitor approved for severe AA in adults. The objective of this study was to describe treatment persistence, effectiveness, treatment patterns and patient satisfaction among individuals with AA receiving baricitinib in routine clinical practice in Spain.
Methods: Observational, cross-sectional and retrospective study conducted in 15 Spanish hospitals.
(Abstract 3, page S227)